Dualitas Therapeutics Signs Research Collaboration and License Agreement With Roche Worth Up to $1 Billion ($36.5M Upfront) to Screen 300,000+ Bispecific Antibody Combinations for Immunology and Inflammation
Dualitas Therapeutics announced Thursday September 17, 2026 a research collaboration and license agreement with Roche worth up to $1 billion (including $36.5 million upfront plus research, development, and commercial milestone payments and tiered royalties) to discover and develop novel bispecific antibody therapeutics for immunology and inflammation (I&I) indications. Dualitas will apply its DualScreen Bispecific Discovery Engine — a proximity-biology-anchored functional-screening platform — to evaluate more than 300,000 novel bispecific combinations, one of the largest bispecific-screening endeavors publicly announced to date. Roche will assume responsibility for all subsequent preclinical development, regulatory, manufacturing, and commercial activities across the collaboration. The Dualitas platform positions bispecifics as vehicles for synergistic activities unattainable with conventional antibodies. The deal follows Roche's growing focus on I&I as one of its stated therapeutic pillars alongside oncology, neuroscience, and cardiometabolic disease. It also extends Roche's recent deal-making momentum, which included the September 8 Alteogen ALT-B4 subcutaneous-conversion licensing agreement worth up to $3.22 billion.